Patents by Inventor Carlos Martinez Alonso
Carlos Martinez Alonso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9884915Abstract: The present invention relates to antibodies binding specifically to CCR9, and to antigen-binding fragments thereof. It also relates to uses thereof and diagnostic methods using said antibodies.Type: GrantFiled: November 25, 2014Date of Patent: February 6, 2018Assignee: Consejo Superior de Investigaciones Cientificas C.S.I.C.Inventors: Sonia Chamorro Pérez, Ana Franco Villanueva, José Alberto García Sanz, Leonor Kremer Barón, Carlos Martínez Alonso, Maria Vela Cuenca, Laura Carramolino Fitera
-
Publication number: 20160257756Abstract: The present invention relates to antibodies binding specifically to CCR9, and to antigen-binding fragments thereof. It also relates to uses thereof and diagnostic methods using said antibodies.Type: ApplicationFiled: November 25, 2014Publication date: September 8, 2016Inventors: Sonia CHAMORRO PÉREZ, Ana FRANCO VILLANUEVA, José Alberto GARCÍA SANZ, Leonor KREMER BARÓN, Carlos MARTÍNEZ ALONSO, María VELA CUENCA, Laura CARRAMOLINO FITERA
-
Patent number: 8182816Abstract: Disclosed are methods of treating subjects having cancers including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.Type: GrantFiled: November 11, 2010Date of Patent: May 22, 2012Assignees: Universidad Autonoma de Madrid, Consejo Superior de Investigaciones CientificasInventors: Francisco Sanchez-Madrid, Carlos-Martinez Alonso, David Sancho Madrid, Pablo Engel Rocamora, Enric Esplugues Artola, Javier Vega Ramos, Pilar Lauzurica Gomez
-
Publication number: 20110165071Abstract: Disclosed are methods of treating subjects having cancers including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.Type: ApplicationFiled: November 11, 2010Publication date: July 7, 2011Inventors: Francisco Sanchez-Madrid, Carlos Martinez Alonso, David Sancho Madrid, Pablo Engel Rocamora, Enric Esplugues Artola, Javier Vega Ramos, Pilar Lauzurica Gómez
-
Publication number: 20110081292Abstract: Disclosed are methods of treating viral hepatitis including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.Type: ApplicationFiled: November 11, 2010Publication date: April 7, 2011Inventors: Francisco Sanchez-Madrid, Carlos-Martinez Alonso, David Sancho Madrid, Pablo Engel Rocamora, Enric Esplugues Artola, Javier Vega Ramos, Pilar Lauzurica Gómez
-
Publication number: 20110059015Abstract: The application relates to antibodies and fragments capable of binding HIV-1 gp120 protein, nucleic acids encoding such proteins, to the use of such proteins to identify active compounds, and to the use of the compounds as vaccines.Type: ApplicationFiled: September 12, 2008Publication date: March 10, 2011Applicants: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS/ CSIC, PHARMACIA SPAINInventors: José Luis Toran Garcia, Carlos Martinez Alonso
-
Patent number: 7867475Abstract: Disclosed are methods of treating subjects having disorders or conditions characterized by an unwanted immune response including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.Type: GrantFiled: February 2, 2004Date of Patent: January 11, 2011Assignees: Universidad Autonoma de Madrid, Consejo Superior de Investigaciones CientificasInventors: Francisco Sanchez-Madrid, Carlos Martinez Alonso, David Sancho Madrid, Pablo Engel Rocamora, Enric Esplugues Artola, Javier Vega Ramos, Pilar Lauzurica Gómez
-
Publication number: 20100227317Abstract: The invention relates to a method for the molecular diagnosis of prostate cancer, comprising the in vitro analysis of the overexpression or underexpression of combinations of genes that can distinguish, with high statistical significance, tumorous prostate samples from non-tumorous prostate samples. The invention also relates to a kit for the molecular diagnosis of prostate cancer, which can perform the above-mentioned detection.Type: ApplicationFiled: February 15, 2007Publication date: September 9, 2010Inventors: Timothy Thomson Okatsu, Raquel Bermudo Gascon, Angel Ramirez Ortiz, David Abia, Carlos Martinez Alonso, Pedro Luis Fernandez Ruiz, Berta Ferrer Fabrega, Elias Campo Guerri, Elisabet Rosell Vives
-
Patent number: 6780644Abstract: The invention relates to the use of prokaryotic beta recombinase in eukaryotic cells, especially for transgenic work in eukaryotic cells. It also relates to the use of prokaryotic beta recombinase for site-specific intramolecular recombination between two six sites in eukaryotic cells. The use of the gene coding for beta recombinase for promoting the deletion of DNA sequences located between directly oriented six sites in mammalian cells and for catalysing site-specific resolution of DNA sequences in an extrachromosomal target introduced into an eukaryotic cell are also disclosed.Type: GrantFiled: September 22, 1998Date of Patent: August 24, 2004Assignees: Pharmacia Spain S.A., Consejo Superior de Investigaciones CientificasInventors: Vincente Días, Fernando Rojo, Carlos Martinez Alonso, Juan C. Alonso, Antonio Bernad
-
Publication number: 20040157332Abstract: The invention relates to the use of prokaryotic beta recombinase in eukaryotic cells, especially for transgenic work in eukaryotic cells.Type: ApplicationFiled: March 24, 2004Publication date: August 12, 2004Inventors: Vincente Dias, Fernando Rojo, Carlos Martinez Alonso, Juan C. Alonso, Antonio Bernad
-
Publication number: 20040106105Abstract: The application relates to antibodies and fragments capable of binding HIV-1 gp120 protein, nucleic acids encoding such proteins, to the use of such proteins to identify active compounds, and to the use of the compounds as vaccines.Type: ApplicationFiled: June 12, 2003Publication date: June 3, 2004Inventors: Jose Luis Toran Garcia, Carlos Martinez Alonso
-
Patent number: 6716594Abstract: The invention relates to monoclonal antibody capable of specific binding to the molecular weight of 20 kDa variant of human growth hormone. This monoclonal antibody has no substantial binding to hGH of molecular weight 22 kDa. The invention also relates to the use of this monoclonal antibody for measurement of hGH 20K, especially in body fluids. The antibodies can be used for detection and quantification of hGH 20K, especially in serum.Type: GrantFiled: June 16, 1999Date of Patent: April 6, 2004Assignees: Pharmacia Spain SA, Consejo Superior de Investigaciones ScientificasInventors: Yngve Elof Hansson, Leonor Kremer Baron, Carlos Martínez Alonso, José Mario Mellado Garcia, José Miguel Rodriguez Frade
-
Patent number: 6645723Abstract: The present invention relates to a method for determinating cytokine receptor, especially growth hormone receptor (GHR), activation, by the use of an antibody capable of discriminating between an activated and an inactive cytokine receptor conformation, especially GHR or growth hormone binding protein (GHBP) conformation, the method comprising: contacting the antibody and the cytokine receptor to form a complex, contacting a candidate ligand to the complex, measuring the antibody binding to inactive cytokine receptor and thereby discriminating between an activated and an inactive conformation. The invention also relates to an antibody directed to the hinge spanning subdomains I and II of the growth hormone receptor extracellular region and which is capable of discriminating between an activated and an inactive receptor conformation. The invention also relates to the use of the antibody for e.g.Type: GrantFiled: March 19, 1998Date of Patent: November 11, 2003Assignees: Consejos Superior de Investigaciones Cientificas, Pharmacia Spain S.A.Inventors: Carlos Martinez Alonso, José Mario Mellado Garcia, Leonor Kremer Baron, José Miguel Rodriguez Frade
-
Publication number: 20030077663Abstract: The present invention relates to a method for determinating cytokine receptor, especially growth hormone receptor (GHR), activation, by the use of an antibody capable of discriminating between an activated and an inactive cytokine receptor conformation, especially GHR or growth hormone binding protein (GHBP) conformation, the method comprising: contacting the antibody and the cytokine receptor to form a complex, contacting a candidate ligand to thc complex, measuring the antibody binding to inactive cytokine receptor and thereby discriminating between an activated and an inactive conformationType: ApplicationFiled: March 19, 1998Publication date: April 24, 2003Inventors: CARLOS MARTINEZ ALONSO, JOSE MARIO MELLADO GARCIA, LEONOR KREMER BARON, JOSE MIGUEL RODRIGUEZ FRADE
-
Patent number: 6495329Abstract: The present invention relates to a method for determinating cytokine receptor, especially growth hormone receptor (GHR), activation, by the use of an antibody capable of discriminating between an activated and an inactive cytokine receptor conformation, especially GHR or growth hormone binding protein (GHBP) conformation, the method comprising: contacting the antibody and the cytokine receptor to form a complex, contacting a candidate ligand to the complex, measuring the antibody binding to inactive cytokine receptor and thereby discriminating between an activated and an inactive conformation. The invention also relates to an antibody directed to the hinge spanning subdomains I and II of the growth hormone receptor extracellular region and which is capable of discriminating between an activated and an inactive receptor conformation. The invention also relates to the use of the antibody for e.g.Type: GrantFiled: March 19, 1998Date of Patent: December 17, 2002Assignees: Pharmacia AB, Consejo Superior de InvestigacionesInventors: Carlos Martinez Alonso, José Mario Mellado Garcia, Leonor Kremer Baron, José Miguel Rodriguez Frade
-
Patent number: 6084075Abstract: The invention relates to antibodies which is capable of binding the monocyte chemoattractant protein 1 (MCP-1) receptor CCR2, especially those which are capable of acting either as an antagonist or agonist. The claimed antobodies can be used for in vitro and/or in vivo diagnostic, for screening and detection of tissues and classes of cells expressing the MCP-1 receptor, for screening for new drugs and for therapeutic use. The invention also relates to a preparation comprising the claimed antibody and a micro-organism or cell-line capable of producing the claimed antibody.Type: GrantFiled: February 28, 1997Date of Patent: July 4, 2000Assignees: Pharmacia & Upjohn AB, Consejo Superior de InvestigacionesInventors: Peter Lind, Carlos Martinez Alonso, Jose Mario Mellado Garcia, Jose Miguel Rodriguez Frade
-
Patent number: 5945296Abstract: The invention relates to monoclonal antibody capable of specific binding to the molecular weight of 20 kDa variant of human growth hormone. This monoclonal antibody has no substantial binding to hGH of molecular weight 22 kDa. The invention also relates to the use of this monoclonal antibody for measurement of hGH 20K, especially in body fluids. The antibodies can be used for detection and quantification of hGH 20K, especially in serum.Type: GrantFiled: March 28, 1997Date of Patent: August 31, 1999Assignees: Pharmacia & Upjohn AB, Consejo Superior de InvestigacionesInventors: Yngve Elof Hansson, Leonor Kremer Baron, Carlos Martinez Alonso, Jose Mario Mellado Garcia, Jose Miguel Rodriguez Frade
-
Patent number: 5776947Abstract: The use of a quinoline-3-carboxamide compound comprising structure (I), optionally with substituents for the hydrogen atoms shown (H.sup.1-9), and a salt of compound (I) where (a) ---- represents that there are two conjugated double bonds between the atoms comprised by the dashed line, (b) X.sub.1 and X.sub.2 are separately selected form an oxygen atom or an NH.sup.9 group, said X.sub.1 and X.sub.2 being bound by a single bond to the ring when attached to H.sup.7 or H.sup.8 and by a double bond when not bound to H.sup.7 or H.sup.8, (c) H.sup.1-9 ; are hydrogens with the provision that H.sup.9 is only present when at least one of X.sub.1 and X.sub.2 is the NH.sup.9 group, (d) H.sup.7 and H.sup.8 are hydrogens that are attached to different atoms selected among X.sub.1, X.sub.2 and the nitrogen atom (N) in the quinoline ring, for the manufacture of a composition intended for inhibiting the production of tumor necrosis factor TNF in a living body and/or the treatment of septic shock in a living body.Type: GrantFiled: May 20, 1996Date of Patent: July 7, 1998Assignee: Pharmacia ABInventors: Guido Peter Kroemer, JoseAngel Gonzalo, Carlos Martinez Alonso, Terje Kalland